Trial Search Results
Utility of At-home Monitoring of Exercise Capacity by App-based 6-minute Walk Test
- Evaluate for accuracy and reproducibility of data collected via the participant-operated Walk.Talk.Track. (WTT) app combined with Apple Watch during in-clinic, technician proctored 6MWT's.
- Determine whether the WTT app on the Apple Watch can accurately collect information on distance traveled and heart rate (HR) during in-clinic 6MWT run by American Thoracic Society (ATS) guidelines
- Determine whether participants can operate the WTT app and Apple Watch effectively to gather accurate data in a monitored and home-based setting
- Prospectively monitor for changes in WTT app recorded 6MWT results following initiation of therapy in a treatment naïve cohort of PAH participants
- Evaluate whether changes from baseline in 6 minute walk distance (6MWD) and heart rate recovery at one minute (HRR1) as well as other variables that have been associated with disease severity in PAH and left-sided heart disease (resting HR, heart rate variability [HRV], chronotropic index [CI]) can be identified before the 12-week follow up when comparing the treatment arm and the control arm
- Evaluate whether changes from baseline in the HRR1, resting HR, HRV and/or CI are more evident in treatment responders when compared to treatment non-responders.
Stanford is currently not accepting patients for this trial.
- Device: Home-based 6 minute walk test
- Diagnosis of WHO Group I Pulmonary Arterial Hypertension (PAH) (Idiopathic (I)PAH,
Heritable PAH (including Hereditary Hemorrhagic Telangiectasia), Associated (A)PAH
(including collagen vascular disorders, drugs+toxins exposure, congenital heart
disease, and portopulmonary disease).
- Do not meet exclusion criteria
- Pulmonary Hypertension due to left heart disease (PH-LHD, WHO group 2), Pulmonary
hypertension due to chronic lung disease (PH-CLD, WHO group 3), Chronic
thrombo-embolic pulmonary hypertension (CTEPH, WHO group 4), pulmonary hypertension
with unclear and/or multi-factorial mechanisms (WHO goup 5)
- Inability to perform a 6 minute walk test (6MWT)
Ages Eligible for Study
18 Years - 70 Years
Genders Eligible for Study